• Streptavidin-HyperFluor 647 Workflow Guide

  2026-08-18

  Streptavidin-HyperFluor 647 converts biotinylated antibodies, nucleic acids, and proximity-labeling products into bright red fluorescence for microscopy and flow analysis. This guide explains how to pair the conjugate with click-compatible BmTyr workflows while avoiding the critical mistake of treating a biotin-free labeling platform as a direct streptavidin assay.

• Aztreonam: Monocyclic β-Lactam Research Guide

  2026-08-17

  Aztreonam is a monocyclic β-lactam antibiotic with selective activity against Gram-negative aerobic bacteria through inhibition of bacterial cell wall synthesis. Product data also support research into bone marrow progenitor cell inhibition, hepatic cytochrome P450 effects, solubility, and controlled compound handling.

• BML-277: Practical Chk2 Inhibitor Workflows

  2026-08-17

  BML-277 combines nanomolar biochemical potency with a cell-compatible concentration range for dissecting checkpoint signaling, T-cell radioprotection, and DNA damage responses. This guide connects reproducible kinase and apoptosis assays with a cautious, hypothesis-driven extension into the CHK2–cGAS–TRIM41 pathway.

• S Tag Peptide A6007: Practical Fusion-Tag Workflow

  2026-08-16

  S Tag Peptide A6007 provides a 15-amino-acid sequence for genetically encoded N- or C-terminal fusion, supporting recombinant protein detection, antibody-based capture, and protein solubility improvement. It should be evaluated as part of a validated fusion construct rather than used as a standalone RNase reagent or assumed to improve every target protein.

• Imipenem: Mechanism-Led Assay Design

  2026-08-15

  Imipenem is a semisynthetic thienamycin antibiotic with a distinctive PBP-centered mechanism. This guide translates its molecular activity into better antibacterial research assays, immune response modulation studies, and sepsis animal model interpretation.

• Nigericin for pH and Mitochondrial Assays

  2026-08-14

  Nigericin converts potassium–proton exchange into measurable changes in intracellular pH, mitochondrial behavior, and cell fate. This practical guide covers stock preparation, dose-finding, cancer-cell workflows, GSDMD-linked readouts, and carefully bounded extensions to metabolic antibiotic research.

• CSB Alkaloid Pharmacokinetics in MASH Mice

  2026-08-14

  The reference study systematically examines how MASH-like liver pathology changes the pharmacokinetics and tissue distribution of three major Corydalis saxicola Bunting total alkaloids. By combining UHPLC-MS/MS exposure profiling with transporter, microsomal metabolism, cellular uptake, and PXR-related analyses, it links disease-associated pharmacokinetic variability to altered CYP450, Oatp1b2, and P-gp activity.

• Spirocyclic POM Analogues Targeting MmpL3 in TB

  2026-08-13

  The reference study develops spirocyclic phenyl oxazole methyl analogues and identifies compound 5c as a potent inhibitor of Mycobacterium tuberculosis, including drug-susceptible and resistant clinical isolates. Its combination of phenotypic screening, spontaneous mutant generation, ADME and pharmacokinetic assessment, cytotoxicity testing, and docking provides a practical framework for advancing MmpL3-directed antitubercular chemistry.

• Busulfan and the Logic of Germline Lineage Tracing

  2026-08-13

  Busulfan is more than a DNA alkylating agent: it is a mechanistically informative perturbation for testing how tissue injury, senescence, and germline depletion reshape biological interpretation. This thought-leadership article connects Busulfan-induced damage models with new dual-recombinase evidence against postnatal neo-oogenesis in mice, while defining practical boundaries for translational research.

• MEK–ERK Control of TERT in Human Stem Cells

  2026-08-12

  The reference preprint identifies a regulatory connection between MEK1/2–ERK signaling, c-Myc:MAX, and polycomb repression of TERT in human embryonic stem cells. Its findings suggest that MAPK activity helps maintain a transcriptionally permissive TERT promoter by limiting H3K27me3 accumulation, providing a mechanistic framework for studying telomere maintenance in pluripotent cells.

• MLN4924: NEDD8-Activating Enzyme Inhibitor

  2026-08-12

  MLN4924 is a potent NEDD8-activating enzyme inhibitor with a reported biochemical IC50 of 4 nM. By blocking NAE-dependent neddylation, it suppresses cullin-RING ligase activity, alters CRL-substrate turnover, and supports cancer biology research in cellular and xenograft models.

• Penicillin G Sodium: Workflow & Troubleshooting

  2026-08-11

  Turn Penicillin G Sodium into a reproducible tool for susceptibility testing, time-kill studies, and infection-model design. This guide combines cell-wall pharmacology, stability-aware handling, and lessons from an intestinal-barrier study to help separate antibacterial activity from host-response effects.

• Faropenem Sodium: From Penem Biology to AMR Strategy

  2026-08-11

  Faropenem sodium offers translational researchers a useful model for connecting PBP-driven cell wall inhibition, transporter biology, antimicrobial spectrum, and stewardship-aware resistance research. This article moves beyond a conventional product description to outline how mechanistic and experimental context should shape study design and interpretation.

• Spirocyclic POM Analogues as MmpL3 Inhibitors

  2026-08-10

  This 2024 Bioorganic Chemistry study develops spirocyclic phenyl oxazole methyl (POM) analogues as anti-tubercular compounds and identifies MmpL3 as the likely target of lead compound 5c. The lead showed activity against drug-susceptible and resistant Mycobacterium tuberculosis isolates, together with favorable early ADME, pharmacokinetic, and cytotoxicity results.

• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-08-09

  The reference study identifies SmD2 acetylation as a regulatory link between core spliceosome activity, BRCA1/FANC cassette-exon selection, and PARP inhibitor response in hepatocellular carcinoma. Its findings support a preclinical strategy that combines HDAC-directed modulation with PARP inhibition to expose DNA repair vulnerabilities beyond classical BRCA mutations.

8017 records 8/535 page Previous Next First page 上5页 678910 下5页 Last page